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INTRODUCTION 
Asthma is a common problem encountered in routine 
clinical practice. Asthma is an episodic, chronic inflam-
matory disease of airways characterized by recurrent 
episodes of dyspnea, cough, wheezing and tightness of 
chest. It occurs in all ages but mostly in early ages of 
life. In India, estimated deaths of 57000 were attribut-
ed to asthma in 2004 *1+ and 2.28% in rural and 1.64% 
in urban areas as per ICMR data of 2010 *2+. The preva-
lence of bronchial asthma is comparatively much more 
in the region of Nellimarla, Vizianagaram where the 
study has been conducted. The area is surrounded by 
several industries like jute industries, pharmaceutical 
industries and ferro- alloys industries. Individuals em-
ployed in these industries are exposed to a host of al-
lergens and dust which irritate the respiratory track 
and provoke oxidative stress which induce bron-
chospasm and culminate in many respiratory disorders 
including Bronchial asthma.  
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Bronchial asthma is a chronic, inflammatory condition 
often triggered by allergy & oxidative stress. Oxidative 
stress, developed from imbalance between oxidants 
and antioxidants, may contribute to origin & develop-
ment of several diseases including bronchial asthma. 
Lungs have the highest exposure to atmospheric oxy-
gen and vulnerable to oxidative damage by oxidants 
and pollutants. The large endothelial surface makes it 
the major target site for circulating oxidants xenobi-
otics. Oxidative damage play one of the essential roles 
in development & persistent of bronchial asthma *3,4,+.  
Reactive oxygen species (ROS) can adversely affect air-
way cells and initiate lipid peroxidation , protein oxida-
tion, DNA modification resulting in enhanced release of 
arachidonic acid from cell membranes, contraction of 
airway smooth muscle, increasing vascular permeabil-
ity, increasing airway reactivity and airway secretion, 
synthesis and release of chemo attractants *5-7+. Cho-
lesterol is the second most abundant lipid component 
of pulmonary surfactant, composing of 10-25% of total 
surfactant lipid. At least 80% of lung cholesterol ap-
pears to be derived from plasma lipoproteins *8, 9+.  
HDL particles of total cholesterol have various anti-
inflammatory and antioxidative properties. HDL im-
proves endothelial function by stimulating endothelial 
nitric oxide production *10+. HDL directly neutralizes 
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lipopolysaccharides derived from Gram negative bacte-
ria and inhibits subsequent production of inflammatory 
cytokines in lungs *11, 12+. Synthesis of alveolar surfac-
tant is also promoted by HDL. Thus HDL-c serves as anti
-inflammatory and antioxidative agent in bronchial 
asthma *13+.  
The levels of serum LDL-c have been implicated in the 
inflammatory cascade in murine model of asthma. Re-
cent finding suggest that LDL-c may modulate the in-
flammatory state of asthmatic airways in humans *14+.  
Existing literatures shows that any abnormal lipid pro-
file & lipid peroxidation can affect the course prognosis 
of bronchial asthma in patients. There are many con-
flicting report regarding the alteration of lipid profile in 
bronchial asthma. Some author’s report that serum 
HDL-c is raised & total cholesterol is increased *15-17+. 
Other that LDL-c registers a decrease in bronchial asth-
ma *18+.  
Therefore we have conducted this study to look for 
lipid profile and lipid peroxidation status in bronchial 
asthma patients of this area. Keeping this in view we 
have measured serum total cholesterol, triglyceride, 
LDL-c, HDL-c & VLDL-c along with plasma superoxide 
dismutase activity & serum MDA level in bronchial 
asthma patients &compared with normal healthy indi-
viduals observe any oxidative stress & dislipidemia in 
bronchial asthma which may affect the disease.   
MATERIALS AND METHODS  
Study design: Case control analytical study  
Ethics approval: Our study was approved by Institution-
al Ethical Committee (IEC) of our institution 
Study location: Department of Biochemistry  
Inclusion criteria: Cases: The study subjects were com-
prised of 50 cases (27 male and 23 female patients) of 
chronic bronchial asthma in between 40years to 60 
years who had attended the OPD of TB and Chest de-
partment and diagnosed by history and clinical exami-
nation. Control: 50 participants, age and sex matched 
healthy individuals (29 male and 21 females) were con-
sidered as control group in this study. 
Exclusion criteria: Smokers, steroid dependent patients 
and those suffering from chronic diseases which are 
likely to affect the lipid profile and oxidative stress 
were excluded from the study.  
Grouping: Group 1: Control, Group 2: Case 
Methodology:  
The cases were assayed for serum lipid profile, plasma 
superoxide dismutase (SOD) and serum Malondialde-
hyde (MDA). Fasting blood sample from each patient 
and control were collected and analyzed for serum to-
tal cholesterol, triglyceride, HDL-c and LDL-c, VLDL- c, 
MDA and plasma SOD.  
The assays of various parameters in this study were as 
follows:- The lipid profile estimation was done by ran-
dom access fully automated analyzer. Principles of 
measurement of different component of lipid profile 
measured in the study are as follows *19+.  
 
Plasma SOD activity was estimated by a modified spec-
trophotometric method as described by Kakkar et al 
*20+. Serum MDA level was assessed by colorimetric 
method with Thiobarbituric acid (TBA) *21+.  
Statistical analysis:  All the parameter between two 
study groups was compared by chi-square test, p-value 
< 0.05 was considered as statistical significant. 
RESULTS 
Gender distribution between two studies groups are 
shown in table no 1.  
Table 1. Distribution of Groups–Gender wise 
Table 2. Biochemical analysis (lipid profile and Lipid 
peroxidation levels) of two study groups 
(Statistical significance: * = p-value <0.05, ** = p- value 
<0.001) 
Serum triglyceride GPO –Trinder method 
Serum total cholesterol CHOD-PAP method 
Serum HDL cholesterol Phosphotungstic Acid 
method 
Serum LDL cholesterol & 
VLDL cholesterol 
Friedwald formula 
 Parameters Case Control 
Mean ± SD Mean ± SD 
  
Lipid pro-
file pa-
rameters 
(mg/dl) 
TG 93.42±6.98 95.48 ± 7.97 
LDL 99.21±12.49 103.44±10.55* 
VLDL 18.68 ± 1.39 19.09 ± 1.59 
HDL 52.32 ± 3.58 44.58 ± 2.58** 
TC 170.2±12.17 167.12 ± 9.67 
Lipid pe-
roxidatio
n marker 
SOD 
(U/ml) 
3.42 ± 0.74 7.16 ± 0.52** 
MDA 
(nmol/L) 
5.91 ± 0.88 3.00 ± 0.40** 
Group Total Male Female 
Number Number 
Control (N=50) 50 29 (58%) 21 (42%) 
Cases (N=50) 50 27 (54%) 23 (46%) 
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Above table shows that mean fasting serum triglycer-
ides value of cases (93.42±6.98mg/dl ) were slightly 
lower as compared to controls (95.48 ±7.97mg/dl ).  
Mean fasting serum total cholesterol of cases 
(170.22±12.17mg/dl ) was slightly higher as compared 
to controls (167.12±9.67mg/dl ).  
Fasting serum HDL and LDL cholesterol level of cases 
respectively (52.32±3.58mg/dl ), (99.21±12.49mg/dl) 
were found to be significantly higher when compared 
to controls (44.58±2.58mg/dl ), (103.44±10.55mg/dl).  
Mean fasting serum VLDL cholesterol of cases 
(18.68±1.39mg/dl ) was lower as compared to controls 
(19.09±1.59mg/dl ), but statistically not significant. 
On comparison of lipid peroxidation status, we found 
that mean plasma SOD level of cases (3.42 ±0.74U/mL) 
was significantly lowered than controls (7.16±0.52U/
mL). Serum MDA level of cases (5.91±0.88nmol/L) was 
higher as compared to controls (3±0.4nmol/L). This 
increase was statistically highly significant. 
DISCUSSION  
In this comparative study 50 patients of bronchial asth-
ma were taken up as cases and 50 healthy individuals 
were considered as controls. To determine their lipid 
profile and lipid peroxidation status, we carried out 
estimation of serum total cholesterol, VLDL-c, HDL-c, 
LDL-c, TG, SOD & MDA level. All the data were tabulat-
ed & compared by suitable statistical test (chi-square). 
On analysis of demographic data of two study group, 
we found that number of male cases were more as 
compared to females. It may be due to more exposure 
of males to environmental factors such as dust, aller-
gen and other air pollutants. Many of the males’ partic-
ipants were industrial workers, employed in nearby 
jute industry. 
FEV (in 1st min, FEV1) of bronchial asthma cases were 
found to be significantly lowered (p< 0.001) in compari-
son to controls.   Asthma is a chronic inflammatory dis-
ease in which ongoing tissue injury and repair may re-
sult in irreversible fibrotic changes in the pulmonary 
airways leading to decline in lung function *22, 23+. Our 
study finding also corroborated with pathophysiology 
of asthma & previous studies. 
On comparison of lipid parameters we found that se-
rum Tg & VLDL-c level in bronchial asthma cases were 
lower & serum total cholesterol was little higher than 
that of controls. Both the findings were statistically not 
significant. Our observations were in concurrence with 
Bahar et. al *17+ & Sahu et al *15+.  
Serum HDL-c level was found significantly higher than 
controls. Similar findings were reported earlier by 
different study groups. Increase in serum HDL-c level 
may be attributed to an increase activity of lecithin 
cholesterol acyl transferase (LCAT) enzyme and its acti-
vator. LCAT catalyses the conversion of surface phos-
pholipids and free cholesterol into lysolecithin and cho-
lesteryl ester. Movement of free cholesterol from cell 
membrane to nascent HDL is also promoted by LCAT. 
The esterified cholesterol is transferred from HDL to 
other lipoproteins with the help of cholesteryl ester 
transport protein (CEAP). Thus cholesteryl esters of 
HDL are transported to liver via chylomicron remnants 
and LDL. The LCAT system in this way involved in the 
removal of excess cholesterol from lipoprotein and its 
excretion through liver. Thus it appears that the rise in 
HDL-c in asthma patients may provide a protection 
from Ischemic heart disease (IHD) and it considered as 
anti-atherogenic. HDL particles have various anti-
inflammatory and anti-oxidative properties. HDL im-
proves endothelial function by stimulating endothelial 
nitric oxide production. Synthesis of alveolar surfactant 
is also promoted by HDL *, 15, 17, 22-24+. 
Serum LDL was found to be significantly lowered in our 
study. Earlier Nakazawa et. al also reported lowering of 
serum LDL in bronchial asthma & hypothesized that LDL 
receptors participate in the delivery of Cholesterol in to 
cells. Therefore with increased LDL receptors acting on 
cell membrane, there may be a resultant decline in 
serum LDL in bronchial asthma patients. This LDL inside 
the cell is necessary for synthesis of pulmonary surfac-
tant *18+.  
In bronchial asthma cases oxidative damage happens 
because of growing production of reactive oxygen spe-
cies (ROS). Increased oxidative stress occurs in the air-
ways of bronchial asthma patients. Inflammatory and 
immune cells in the airways, such as macrophages, 
neutrophill and eosinophills release increased amounts 
of reactive oxygen species through Interleukins. These 
ROS can result in lung injury as a result of direct oxida-
tive damage to epithelial cells and cells shedding. Ac-
tion of ROS can produce many pathological features 
including changes in biochemical microenvironment 
with enhanced arachidonic acid release, increase syn-
thesis of chemo attractant, glucocorticoids, resistance 
and impaired β-adrenergic responsiveness. This effect 
lead to airways smooth muscle contraction, increase 
airways reactivity, secretions and increased vascular 
permeability. Plenty of mediators including lipid media-
tors, chemokines, adhesion molecules and esinophil 
granule proteins (EPO) are promoters of ROS in pa-
tients of asthma. To neutralize this increased produc-
tion of ROS, especially O2
•- free radicals, SOD are in-
creasingly utilized. Thus a decline in plasma SOD level 
in bronchial asthma patients is anticipated. Similar find-
ing of significant decrease of SOD level in bronchial 
asthma cases was observed in comparison to healthy 
controls in our study *25+.  
 We observed that serum MDA level in bronchial asth-
ma cases is significantly raised as compared to the con-
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trol. Increased in MDA is expected in situations of in-
creased oxidative stress. As described earlier increased 
oxidative stress in bronchial asthma also initiates lipid 
peroxidation.  Once lipid peroxidation is initiated, a 
propagation of chain reactions will take place until ter-
mination products are produced. The main primary 
products of lipid peroxidation are lipid hydro peroxides. 
Among the many different aldehydes which can be 
formed as secondary products during lipid peroxidation 
are Malondialdehydes (MDA), propanal, hexanal and 4-
Hydroxynonenal (4-HNE). MDA appears to be most 
mutagenic product and 4-HNE is the most toxic. Arachi-
donic acid is increased in airway inflammatory cells of 
bronchial asthmatic patients. This arachidonic acid may 
undergo oxidation to produce end product of lipid pe-
roxidation. So MDA is increased in bronchial asthma 
due to generation by decomposition of arachidonic acid 
and larger PUFA through enzymatic and nonenzymatic 
processes. It is more chemically stable and membrane 
permeable than ROS and less toxic than 4-HNE.  Once 
formed MDA can be enzymatically metabolized or can 
react on cellular and tissue proteins or DNA to form 
adducts resulting in bimolecular damage *26-29+. 
CONCLUSION  
In conclusion lipid profile in bronchial asthma patients   
(raised HDL& decreased LDL) provides some degree of 
protection to this patients against ischemic heart dis-
ease (IHD). But increase in lipid peroxidation as evi-
denced by decreased plasma SOD & raised serum MDA 
aggravate airway inflammation, smooth muscle con-
traction & increased vascular permeability.  
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